BACKGROUND: Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination. PATIENTS AND METHODS: Fourteen patients with advanced disease and nine patients in adjuvant setting received IFO 12.5 g/m2 in 120-hour continuous infusion with Mesna uroprotection and ADM 20 mg/m2 on days 1-3 and G-CSF every three weeks. RESULTS: Twenty-three patients received 89 chemotherapy cycles (70 cycles at full dose). Seventeen patients received the planned treatment, and nine patients required dose reductions. We observed grade 3-4 neutropenia in 52 cycles (59%)/20 patients; grade 3-4 thrombocytopenia in 16 cycles (18%)/nine patients; grade 3-4 anaemia in 24 cycles (27%)/11 patients. Eight patients experienced febrile neutropenia and six patients required blood transfusions. CONCLUSIONS: While feasible, this regimen showed heavy toxicity. Nevertheless, 74% of the patients were able to complete the planned treatment. Adjustment of the schedule of IFO continuous infusion to improve this combination is currently under investigation.
BACKGROUND:Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination. PATIENTS AND METHODS: Fourteen patients with advanced disease and nine patients in adjuvant setting received IFO 12.5 g/m2 in 120-hour continuous infusion with Mesna uroprotection and ADM 20 mg/m2 on days 1-3 and G-CSF every three weeks. RESULTS: Twenty-three patients received 89 chemotherapy cycles (70 cycles at full dose). Seventeen patients received the planned treatment, and nine patients required dose reductions. We observed grade 3-4 neutropenia in 52 cycles (59%)/20 patients; grade 3-4 thrombocytopenia in 16 cycles (18%)/nine patients; grade 3-4 anaemia in 24 cycles (27%)/11 patients. Eight patients experienced febrile neutropenia and six patients required blood transfusions. CONCLUSIONS: While feasible, this regimen showed heavy toxicity. Nevertheless, 74% of the patients were able to complete the planned treatment. Adjustment of the schedule of IFO continuous infusion to improve this combination is currently under investigation.
Authors: A López-Pousa; J Martín; J Montalar; R de Las Peñas; J García Del Muro; J Cruz; J Maurel; P Escudero; A Casado; J M Buesa Journal: Sarcoma Date: 2006
Authors: S Leyvraz; R Herrmann; L Guillou; H P Honegger; A Christinat; M F Fey; C Sessa; M Wernli; T Cerny; D Dietrich; B Pestalozzi Journal: Br J Cancer Date: 2006-10-10 Impact factor: 7.640
Authors: D Bafaloukos; C Papadimitriou; H Linardou; G Aravantinos; P Papakostas; D Skarlos; P Kosmidis; G Fountzilas; H Gogas; C Kalofonos; A M Dimopoulos Journal: Br J Cancer Date: 2004-11-01 Impact factor: 7.640
Authors: Vittoria Colia; Marco Fiore; Salvatore Provenzano; Elena Fumagalli; Rossella Bertulli; Carlo Morosi; Angelo P Dei Tos; Marta Barisella; Alessandro Gronchi; Paolo G Casali; Roberta Sanfilippo Journal: Clin Sarcoma Res Date: 2017-08-22